MB-VEGF-C

MB-VEGF-C is an engineered variant of vascular endothelial growth factor C (VEGF-C) designed with an extracellular matrix (ECM)-binding domain. This modification allows the protein to be retained within the tumor microenvironment following intratumoral injection, preventing systemic exposure while promoting localized lymphangiogenesis. Developed by researchers at the University of Chicago, MB-VEGF-C aims to enhance antitumor immunity by increasing the density of lymphatic vessels, which facilitates the infiltration of cross-presenting dendritic cells and T cells into the tumor. In preclinical melanoma models, it has demonstrated the ability to convert "cold" tumors into "hot" tumors and restore responsiveness to immune checkpoint inhibitors.

Other names

matrix-binding VEGF-CECM-binding VEGF-C